Idhifa
Active Ingredient(s): EnasidenibFDA Approved: * August 1, 2017
Pharm Company: * CELGENE CORP
Category: Cancer
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
Idhifa Overview
Enasidenib (INN; trade name Idhifa) is a medication used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test.[1] It is an inhibitor of IDH2. It was developed by Agios Pharmaceuticals and is licensed to Celgene for further development. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[2...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Enasidenib
Recent Idhifa Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Enasidenib
- Tablet: 100mg, 50mg
NDC Database Records for Idhifa: (2 results)
Sorted by National Drug Code- 59572-705 Idhifa 50 mg Oral Tablet, Film Coated by Celgene Corporation
- 59572-710 Idhifa 100 mg Oral Tablet, Film Coated by Celgene Corporation